{"result": "(\"entity\"<|>LIRAGLUTIDA<|>PERSON<|>Liraglutida is a GLP-1 receptor agonist used for weight loss and diabetes management, administered at a dose of 1.8 mg per day with significant weight loss effects.)\n##\n(\"entity\"<|>SEMAGLUTIDA<|>PERSON<|>Semaglutida is a GLP-1 receptor agonist administered at doses of 0.5-1 mg weekly, known for achieving superior weight loss compared to other weekly analogs.)\n##\n(\"entity\"<|>DULAGLUTIDA<|>PERSON<|>Dulaglutida is a GLP-1 receptor agonist administered weekly, used for diabetes management and weight loss.)\n##\n(\"entity\"<|>EXENATIDE-LAR<|>PERSON<|>Exenatide-LAR is a GLP-1 receptor agonist administered weekly, used for diabetes management.)\n##\n(\"entity\"<|>GASTRECTOMÍA VERTICAL<|>EVENT<|>Gastrectomía vertical is a surgical procedure aimed at weight loss, often used in patients with severe obesity.)\n##\n(\"entity\"<|>BYPASS GÁSTRICO<|>EVENT<|>Bypass gástrico is a surgical procedure for weight loss that alters the digestive system to limit food intake and absorption.)\n##\n(\"entity\"<|>SUSTAIN-7<|>EVENT<|>SUSTAIN-7 is a randomized comparative study evaluating the effects of semaglutida and dulaglutida on HbA1c and weight loss.)\n##\n(\"entity\"<|>DIABETES<|>PERSON<|>Diabetes is a chronic condition that affects the body's ability to process blood sugar, requiring management strategies including medication and lifestyle changes.)\n##\n(\"entity\"<|>HIPERTENSIÓN<|>PERSON<|>Hipertensión is a condition characterized by consistently high blood pressure, often requiring medical intervention and lifestyle adjustments.)\n##\n(\"entity\"<|>DISLIPIDEMIA<|>PERSON<|>Dislipidemia refers to abnormal levels of lipids in the blood, which can increase the risk of cardiovascular diseases.)\n##\n(\"entity\"<|>OBESIDAD<|>PERSON<|>Obesidad is a medical condition characterized by excessive body fat, often leading to various health complications.)\n##\n(\"entity\"<|>SAHS<|>PERSON<|>SAHS, or síndrome de apnea-hipopnea del sueño, is a sleep disorder characterized by repeated interruptions in breathing during sleep.)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>GASTRECTOMÍA VERTICAL<|>Liraglutida is used to enhance weight loss outcomes in patients undergoing gastrectomía vertical<|>7)\n##\n(\"relationship\"<|>SEMAGLUTIDA<|>GASTRECTOMÍA VERTICAL<|>Semaglutida is used to improve weight loss results in patients who have undergone gastrectomía vertical<|>7)\n##\n(\"relationship\"<|>DULAGLUTIDA<|>GASTRECTOMÍA VERTICAL<|>Dulaglutida may be used in conjunction with gastrectomía vertical to aid in weight management<|>6)\n##\n(\"relationship\"<|>EXENATIDE-LAR<|>GASTRECTOMÍA VERTICAL<|>Exenatide-LAR can be prescribed to support weight loss after gastrectomía vertical<|>6)\n##\n(\"relationship\"<|>SEMAGLUTIDA<|>SUSTAIN-7<|>Semaglutida was evaluated in the SUSTAIN-7 study for its effects on HbA1c and weight loss<|>8)\n##\n(\"relationship\"<|>DULAGLUTIDA<|>SUSTAIN-7<|>Dulaglutida was compared to semaglutida in the SUSTAIN-7 study regarding its impact on weight and HbA1c<|>8)\n##\n(\"relationship\"<|>DIABETES<|>LIRAGLUTIDA<|>Liraglutida is used to manage diabetes by improving glycemic control<|>9)\n##\n(\"relationship\"<|>DIABETES<|>SEMAGLUTIDA<|>Semaglutida is prescribed for diabetes management, aiding in blood sugar control<|>9)\n##\n(\"relationship\"<|>HIPERTENSIÓN<|>OBESIDAD<|>Hipertensión is often a comorbidity associated with obesidad<|>7)\n##\n(\"relationship\"<|>DISLIPIDEMIA<|>OBESIDAD<|>Dislipidemia frequently occurs in individuals with obesidad<|>7)\n##\n(\"relationship\"<|>SAHS<|>OBESIDAD<|>SAHS is commonly found in patients suffering from obesidad<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ugía metabólica y cumpliendo además                        dos requisitos: que la                              COMENTARIO\n         HbA1c esté en el rango de normalidad (a efectos prácticos también se considera HbA1c <                                                           La paciente tiene varios objetivos para controlar (diabetes, hipertensión, dislipidemia, po-\n         6%) y que la glucemia también esté por debajo de 100 mg/dl.                                                                                      sible síndrome de apnea-hipopnea del sueño [SAHS]) todos ellos muy relacionados con el\n\n\n\n438                                                                                                                                                                                                                                                                                      439\n---\n                                                                                                                                                                                                                           OBESIDAD,               LÍPIDOS                      8\n                                                                                                                                                                                             Y TRASTORNOS ELECTROLÍTICOS\n\n\n\n         exceso ponderal. Por tanto, requiere una aproximación terapéutica múltiple. Pero, centrán-                                                      eventraciones de la laparotomía y la recuperación funcional del paciente es mucho más\n         donos en su diabetes, cualquiera de las opciones mejoraría con mayor o menor certeza                                                            rápida.\n         su control glucémico, con una disminución del                    0,8-1,5% de reducción de           HbA1c. Pero, si                             En una paciente con un IMC de 59 kg/m2, una pérdida de peso sostenida mayor del 30% del\n         añadimos un fármaco que tenga una acción adicional sobre el peso, la mejoría metabólica                                                         peso inicial sería suficiente para mejorar las comorbilidades asociadas. Estos objetivos de\n         global se incrementaría.                                                                                                                        pérdida de peso se consiguen mediante gastrectomía vertical (o tubular) o bypass gástrico. El\n         Las sulfonilureas pueden incrementar el peso; los inhibidores de la dipeptidil peptidasa-4                                                      resultado final alcanzado sería un IMC de 41 kg/m2, una situación aún de obesidad mórbida.\n         (DPP4) tienen un efecto neutro sobre el peso, y los fármacos glucosúricos pueden disminuir                                                      Considerando que, transcurridos unos 3-5 años, puede existir una recuperación ponderal va-\n         entre 2 y 4 kg de peso (posiblemente en esta paciente porcentualmente algunos kilos más).                                                       riable superior al 10% del peso corporal en un 30-50% de los pacientes, no parece que la gas-\n         Los agonistas del receptor de GLP-1 contribuyen a una pérdida de peso en torno a un pro-                                                        trectomía vertical o el bypass gástrico sean la opción más plausible, como cirugía definitiva.\n         medio de 2-3 kg según los ensayos clínicos realizados. La liraglutida, en dosis de 1,8 mg/                                                      En los casos de superobesidad mórbida (con IMC ≥ 50 kg/m2), la técnica de elección con\n         día,  es el agonista GLP-1 de            administración       diaria con     mayor    pérdida    ponderal     (una di-                          más garantías de éxito tanto en el peso como en la remisión de comorbilidades son las\n         ferencia media de -2,1          kg respecto      a otros    comparadores). La semaglutida,               en  dosis de                           derivaciones biliopancreáticas (o un bypass gástrico distal). Aunque se puede realizar en\n         0,5-1 mg/semanal, consigue reducciones de peso claramente superiores a otros análogos                                                           un solo acto quirúrgico por equipos de cirujanos expertos, en casos como el referido, con\n         de administración semanal (como exenatide-LAR o dulaglutida).                                                                                   múltiples comorbilidades metabólicas y posible SAOS, se puede optar por realizar una ci-\n         En   el estudio aleatorizado comparativo               entre semaglutida y dulaglutida (SUSTAIN-7), en                                          rugía en dos tiempos: primero una gastrectomía vertical, y cuando haya perdido peso y se\n         dosis de 0,5 mg y 0,75 mg, respectivamente, la disminución de HbA1c fue de -1,5% vs. -1,1%                                                      encuentre en el nadir, realizar un segundo tiempo quirúrgico que, sobre una gastroplastia\n         (p < 0,0001) y el peso de -4,6 kg vs. -2,6 kg (p < 0,0001), respectivamente. Con un incremento                                                  vertical, las opciones quedan reducidas a un cruce duodenal, a una variante del cruce duo-\n         de la dosis de 1 mg y 1,75 mg, el descenso de HbA1c fue -1,8% vs. -1,4% y el peso -6,5 kg                                                       denal en un asa (SADI-S) o a un bypass gástrico distal.\n         vs. -3,0 kg (p < 0,0001), respectivamente.                                                                                                      Si la técnica elegida o con experiencia para el\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}